Acquiring Company
Eli Lilly and Company
Acquired Company
Calytrix Bio
Description
Eli Lilly agreed on Monday to buy Calytrix Bio, a Wellesley, Massachusetts biotech developing treatments for myeloproliferative neoplasms, for up to $1.5 billion. The deal includes an upfront payment plus payouts tied to undisclosed clinical and regulatory milestones. Calytrix's CALR-targeting biparatopic antibody is the key asset Lilly is acquiring. The purchase adds to Lilly's streak of more than 15 acquisitions this year.
Other recent acquisitions in Medical and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- PAI Pharma acquires Nexus Pharmaceuticals (November 12, 2026)
- Globus Medical acquires Synaptive Medical (November 3, 2026)
- Indivior Pharmaceuticals Completes Acquisition of Supernus Pharmaceuticals (November 2, 2026)
- Western Microsurgical acquires Q Surgical and Proficient Surgical (October 27, 2026)
- Zeria Pharmaceutical acquires Haupt Pharma Wulfling (October 25, 2026)
- Laprophan acquires Corporate Investment Holding (October 21, 2026)
Who to call at Eli Lilly and Company, and when
When Eli Lilly and Company changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Eli Lilly and Company raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Eli Lilly and Company, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Eli Lilly and Company. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Eli Lilly and Company makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Calytrix Bio?
Calytrix Bio was acquired by Eli Lilly and Company, based in Indianapolis. The deal was reported on November 16, 2026. Lilly is a medicine company turning science into healing to make life better for people around the world. Eli Lilly and Company is publicly traded (LLY) and operates in Manufacturing.
When did Eli Lilly and Company acquire Calytrix Bio?
Eli Lilly and Company's acquisition of Calytrix Bio was reported on November 16, 2026. Eli Lilly agreed on Monday to buy Calytrix Bio, a Wellesley, Massachusetts biotech developing treatments for myeloproliferative neoplasms, for up to $1.5 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Calytrix Bio do?
Calytrix Bio is a privately held biotechnology company developing precision, disease-modifying therapies for myeloproliferative neoplasms. Its initial focus is mCALR-driven essential thrombocythemia and myelofibrosis. It is privately held, operating in Biotechnology, and is based in Massachusetts.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.